drugset / Trial / NCT06682546
A Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride in Gastroscopy/Colonoscopy
RandomizedParallel-groupSingle-blindOther
Summary
A total of 78 subjects undergoing gastroscopy/colonoscopy were randomly assigned to the methoxetomidate hydrochloride group and the etomidate group according to the ratio of 1:1:1 with etomidate as the control group, 26 cases in each group. All subjects were blinded to treatment allocation. Screening assessments for all subjects will be completed within D-14 to D-2 before the first dose. For all subjects who received the investigational drug, they were required to return to the research center on D2-5 to complete the corresponding examination before being discharged from the group. To preliminarily evaluate the efficacy and safety of ET-26 in gastroscopy/colonoscopy.
Timeline
- Start
- 2024-11-15
- Primary completion
- 2024-12-27
- Completion
- 2024-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etomidate | Small molecule | 0.3 mg/kg | Intravenous |
| Subject | Methoxyethyl Etomidate | Unknown | 0.6 mg/kg | Intravenous |
| Subject | Methoxyethyl Etomidate | Unknown | 0.8 mg/kg | Intravenous |
Indications
No indication recorded.